Impedimed Ltd (ASX: IPD) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Impedimed Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Impedimed Ltd (ASX: IPD)
Latest News
![Businessman walks through exit door signalling resignation](https://www.fool.com.au/wp-content/uploads/2020/08/Resignation-16.9-400x225.jpg)
Share Market News
2 ASX All Ords shares tumbling following leadership shakeups
![Happy healthcare workers in a labs](https://www.fool.com.au/wp-content/uploads/2022/05/Biotech-medical-research-400x225.jpg)
Healthcare Shares
3 ASX healthcare stocks that have more than doubled in a year
![A worried man holds his head and look at his computer.](https://www.fool.com.au/wp-content/uploads/2022/03/tax-400x225.jpg)
Share Fallers
Why Brainchip, Impedimed, Northern Star, and Telix shares are falling today
![A man looks down with fright as he falls towards the ground.](https://www.fool.com.au/wp-content/uploads/2022/05/Man-falling-from-sky-16_9-400x225.jpg)
Share Fallers
Why Dusk, Impedimed, Nufarm, and Weebit Nano shares are falling
![A woman jumps for joy with a rocket drawn on the wall behind her.](https://www.fool.com.au/wp-content/uploads/2021/11/Woman-flies-in-rocket-16_9-400x225.jpg)
Healthcare Shares
Guess which ASX biotech share just rocketed 86% on 'a major validating moment'
![Three people in a corporate office pour over a tablet, ready to invest.](https://www.fool.com.au/wp-content/uploads/2022/02/Three-keen-investors-16_9-400x225.jpg)
Earnings Results
3 ASX All Ords shares making moves today following earnings, one up 16%
![Three rock climbers hang precariously off a steep cliff face, each connected to the other with the higher person holding on and the two below them connected by their arms and rope but not making contact with the cliff face.](https://www.fool.com.au/wp-content/uploads/2022/05/fallen-400x225.jpg)
Earnings Results
3 ASX All Ords shares tumbling lower following full-year results
![A man in a white coat holds a laptop in one hand and his head in the other, it's bad news.](https://www.fool.com.au/wp-content/uploads/2021/10/Health-practitioner-bad-news-16_9-400x225.jpg)
Healthcare Shares
Impedimed (ASX:IPD) share price dips following capital raising update
![A doctor in a white coat with a stethoscope around his neck stands in the hallway of a hospital deep in concentration over a tablet device in his hands.](https://www.fool.com.au/wp-content/uploads/2021/10/GettyImages-1151626925-1-400x225.jpg)
Healthcare Shares
What's going on with the Impedimed (ASX:IPD) share price?
![Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.](https://www.fool.com.au/wp-content/uploads/2021/10/scientists-16_9-1-400x225.jpg)
Share Gainers
The Impedimed (ASX:IPD) share price is up 10% on trial success
![A drawing of a rocket follows a chart up, indicating share price lift](https://www.fool.com.au/wp-content/uploads/2021/04/rocket-5-400x225.jpg)
Share Market News
Why the Impedimed (ASX:IPD) share price is rocketing 9% today
![heavy lifting, lifting index, carrying weight, boy lifting dumbbell above his head](https://www.fool.com.au/wp-content/uploads/2021/07/GettyImages-467771153-1-400x225.jpg)
Share Gainers
Impedimed (ASX:IPD) share price rises with 46% lift in revenues
Frequently Asked Questions
-
No, Impedimed does not pay shareholder dividends at this time.
-
Impedimed Limited listed on the ASX on 24 October 2007.
IPD ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Impedimed Ltd
Impedimed Ltd (ASX: IPD) is a global leader in the design and manufacture of medical devices that use bioimpedance spectroscopy (BIS) technologies in the non-invasive clinical assessment of fluid and tissue composition.
The company's products are typically used to assess and monitor lymphedema and heart failure, as well as to measure patients' tissue composition and fluid status. They also have general health applications in weight management, nutritional issues, and assessing bone content.
As well, Impedimed offers a cloud-based digital platform to manage patient data. The company is based in Australia and generates most of its revenue in North America.
IPD Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
26 Jul 2024 | $0.07 | $0.00 | 0.00% | 2,186,636 | $0.07 | $0.07 | $0.06 |
25 Jul 2024 | $0.07 | $0.00 | 0.00% | 1,092,137 | $0.07 | $0.07 | $0.07 |
24 Jul 2024 | $0.07 | $0.00 | 0.00% | 444,621 | $0.07 | $0.07 | $0.07 |
23 Jul 2024 | $0.07 | $0.00 | 0.00% | 690,689 | $0.07 | $0.07 | $0.07 |
22 Jul 2024 | $0.07 | $0.00 | 0.00% | 195,166 | $0.07 | $0.07 | $0.07 |
19 Jul 2024 | $0.06 | $0.00 | 0.00% | 4,377,162 | $0.07 | $0.07 | $0.06 |
18 Jul 2024 | $0.07 | $0.00 | 0.00% | 2,939,307 | $0.06 | $0.07 | $0.06 |
17 Jul 2024 | $0.06 | $0.00 | 0.00% | 5,102,295 | $0.06 | $0.07 | $0.06 |
16 Jul 2024 | $0.07 | $0.00 | 0.00% | 3,912,309 | $0.07 | $0.07 | $0.06 |
15 Jul 2024 | $0.07 | $0.00 | 0.00% | 3,134,429 | $0.07 | $0.07 | $0.07 |
12 Jul 2024 | $0.07 | $0.00 | 0.00% | 1,558,695 | $0.07 | $0.07 | $0.07 |
11 Jul 2024 | $0.07 | $0.00 | 0.00% | 1,524,195 | $0.07 | $0.07 | $0.07 |
10 Jul 2024 | $0.07 | $0.00 | 0.00% | 528,767 | $0.07 | $0.07 | $0.07 |
09 Jul 2024 | $0.07 | $0.00 | 0.00% | 2,411,779 | $0.07 | $0.07 | $0.07 |
08 Jul 2024 | $0.07 | $0.00 | 0.00% | 2,229,167 | $0.07 | $0.07 | $0.07 |
05 Jul 2024 | $0.07 | $0.00 | 0.00% | 573,050 | $0.07 | $0.07 | $0.07 |
04 Jul 2024 | $0.07 | $0.00 | 0.00% | 696,742 | $0.07 | $0.07 | $0.07 |
03 Jul 2024 | $0.07 | $0.00 | 0.00% | 1,314,849 | $0.07 | $0.07 | $0.07 |
02 Jul 2024 | $0.07 | $0.00 | 0.00% | 603,258 | $0.07 | $0.07 | $0.07 |
01 Jul 2024 | $0.07 | $0.00 | 0.00% | 231,936 | $0.07 | $0.07 | $0.07 |
28 Jun 2024 | $0.07 | $0.00 | 0.00% | 3,483,886 | $0.07 | $0.07 | $0.07 |
27 Jun 2024 | $0.07 | $0.00 | 0.00% | 578,028 | $0.07 | $0.07 | $0.07 |
26 Jun 2024 | $0.07 | $0.01 | 15.38% | 1,361,723 | $0.07 | $0.07 | $0.07 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
14 May 2024 | Christine Emmanuel-Donnelly | Buy | 100,000 | $8,000 |
On-market trade.
|
08 May 2024 | Janelle Delaney | Buy | 634,177 | $50,099 |
On-market trade.
|
06 May 2024 | Andrew Grant | Buy | 100,000 | $8,050 |
On-market trade.
|
25 Mar 2024 | Janelle Delaney | Buy | 568,181 | $49,999 |
On-market trade.
|
22 Mar 2024 | Janelle Delaney | Buy | 581,395 | $49,999 |
On-market trade.
|
04 Mar 2024 | Janelle Delaney | Buy | 1,137,634 | $99,591 |
On-market trade.
|
29 Feb 2024 | Andrew Grant | Buy | 100,000 | $87,000 |
On-market trade.
|
28 Feb 2024 | Andrew Grant | Buy | 130,000 | $10,920 |
On-market trade.
|
28 Feb 2024 | Christine Emmanuel-Donnelly | Buy | 121,952 | $10,169 |
On-market trade.
|
14 Dec 2023 | Janelle Delaney | Buy | 942,232 | $135,148 |
On-market trade.
|
13 Dec 2023 | Christine Emmanuel-Donnelly | Buy | 67,857 | $9,499 |
On-market trade.
|
05 Dec 2023 | Janelle Delaney | Buy | 66,503 | $8,977 |
On-market trade.
|
04 Dec 2023 | Andrew Grant | Buy | 70,000 | $9,625 |
On-market trade.
|
20 Nov 2023 | Richard Valencia | Expiry | 20,000,000 | $2,600,000 |
As advised by the company. Lapse of Options and Performance Rights
|
20 Nov 2023 | Richard Valencia | Expiry | 10,000,000 | $1,300,000 |
Options expired.
|
01 Nov 2023 | Christine Emmanuel-Donnelly | Buy | 100,000 | $10,500 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Dr Parmjot Bains | Managing DirectorChief Executive Officer | Jan 2024 |
Dr Bains is a healthcare executive with experience including strategy, sales & marketing, commercial execution, and change management across the US, Asia, Middle East and Australia. Dr Bains joined Pfizer US in 2015 and since then has held several roles located in the United States, Asia Pacific and Middle East. Most recently, Dr Bains was Pfizers Gulf Cluster Country Manager, responsible for setting commercial strategy, aligning team capabilities, driving private and public reimbursement, accelerating sales & marketing activities and key account management. Dr Bains managed a large team across six countries and six therapeutic areas (including breast cancer). Dr Bains former roles include: joint CEO and Chief Operating Officer at Neuren Pharmaceuticals (ASX: NEU) (developing therapies for brain injury, neurodevelopmental and neurodegenerative disorder); CEO of Perseis Therapeutics, (creating monoclonal antibody candidates against breast cancer targets); manager at McKinsey and Company and medical doctor.
|
Mr Andrew John Grant | Non-Executive Director | Sep 2023 |
--
|
Mr McGregor Grant | Executive ChairmanExecutive DirectorChief Financial Officer | Feb 2024 |
--
|
Ms Christine Emmanuel-Donnelly | Non-Executive Director | Sep 2023 |
--
|
Ms Janelle Delaney | Non-Executive Director | Sep 2023 |
--
|
Ms Fiona Bones | Non-Executive Director | Jun 2024 |
Ms Bones is currently VP of Finance, International Controller at Google and has worked at Google for over 20 years. Ms Bones rings global experience in finance, corporate governance, and systems transformation.
|
Ms Leanne Ralph | Company Secretary | Jan 2015 |
-
|
Timothy Cruickshank | Chief Financial Officer |
-
|
|
Shashi Tripathi | Chief Operating Officer |
-
|
|
Joann Yao | Chief Strategy Officer |
-
|
|
Leanne Ralph | Company Secretary |
-
|
|
Dennis Schlaht | Senior Vice President R&D and Technology |
-
|
|
Lisa Prom | Vice President Sales |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
National Nominees Limited | 190,580,959 | 9.44% |
Citicorp Nominees Pty Limited | 176,271,813 | 8.73% |
J P Morgan Nominees Australia Pty Limited | 122,801,902 | 6.08% |
HSBC Custody Nominees (Australia) Limited | 86,660,527 | 4.29% |
Bnp Paribas Noms Pty Ltd | 71,262,491 | 3.53% |
BNP Paribas Nominees Pty Ltd | 56,357,329 | 2.79% |
HSBC Custody Nominees (Australia) Limited i | 47,593,537 | 2.36% |
HSBC Custody Nominees (Australia) Limited A/C 2 | 28,525,714 | 1.42% |
Moore Family Nominee Pty Ltd | 22,500,000 | 1.11% |
Mba Investments Pty Ltd | 22,490,990 | 1.11% |
Mr Hamish Alexander Jones | 21,263,705 | 1.05% |
Mr Gregory Wayne Brown | 21,100,000 | 1.05% |
Sunlora Pty Ltd | 19,000,000 | 0.94% |
Apex Investment Management Pty Limited | 17,471,778 | 0.87% |
BNP Paribas Nominees Pty Ltd i | 16,201,010 | 0.82% |
Pakasoluto Pty Limited | 16,011,422 | 0.79% |
Mr Stephen Edward Mahnken & Mrs Dior Leone Mahnken | 16,000,000 | 0.79% |
Dr Hsien Michael Soo | 15,394,710 | 0.76% |
Bsd Pty Ltd | 13,300,000 | 0.66% |
Mid Dig Investments Pty Ltd | 12,970,633 | 0.64% |